Focus: Debiopharm is a Swiss-based CDMO (Contract Development & Manufacturing Organization) specializing in oncology, infectious diseases, and other therapeutic areas with a lean team of 1-50 employees. The company operates as a private entity focused on contract development and manufacturing services rather than proprietary drug development.
Profile data last refreshed 3h ago · AI intelligence enriched 2mo ago
Cooling — net -6 jobs in 30d
6 added, 12 removed. Slower than typical.
Best suited for early-stage specialists seeking hands-on CDMO/manufacturing experience and oncology pipeline exposure; avoid if you need structured career progression or large-company resources.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Debiopharm
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Debiopharm's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination With Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer - Business Wire
Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination With Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer Business Wire
8-K Filing: Tango Therapeutics, Inc. (TNGX) (CIK 0001819133) — EX-99.1
EX-99.1
8-K Filing: Aprea Therapeutics, Inc. (APRE) (CIK 0001781983) — EXHIBIT 99.3
EXHIBIT 99.3
Genome & Company raises $20 mil. to push novel-target ADC pipeline - koreabiomed.com
Genome & Company raises $20 mil. to push novel-target ADC pipeline koreabiomed.com
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo